Ibrutinib Inhibits B-Cell Adhesion and Causes An Efflux Of Chronic Lymphocytic Leukemia Cells From The Tissue Microenvironment Into The Blood Leading To a Transient Treatment-Induced Lymphocytosis.
Mustafa R, Herman S, Jones J et al.
Key Points:
Phase II single agent trial investigated in vivo effect of ibrutinib on cell adhesion.
Used functional assey that models tumor-stromal interactions in the tissue microenvironment.
Cells from patients treated with ibrutinib showed reduction to adhere to extracellular matrix compared to matching pre-treatment cells.
Implications:
- Ibrutinib directly interferes with intracellular signaling network required for cell adhesion.
View the original abstract on the ASH website.
